Insulet EBITDA Margin 2010-2025 | PODD
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Insulet (PODD) over the last 10 years. The current EBITDA margin for Insulet as of March 31, 2025 is .
| Insulet EBITDA Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM EBITDA | EBITDA Margin |
| 2025-03-31 | $2.20B | $0.43B | 19.32% |
| 2024-12-31 | $2.07B | $0.39B | 18.81% |
| 2024-09-30 | $1.99B | $0.38B | 19.35% |
| 2024-06-30 | $1.87B | $0.35B | 18.62% |
| 2024-03-31 | $1.78B | $0.32B | 18.18% |
| 2023-12-31 | $1.70B | $0.29B | 17.26% |
| 2023-09-30 | $1.56B | $0.21B | 13.35% |
| 2023-06-30 | $1.47B | $0.15B | 10.44% |
| 2023-03-31 | $1.37B | $0.09B | 6.80% |
| 2022-12-31 | $1.31B | $0.10B | 7.74% |
| 2022-09-30 | $1.24B | $0.13B | 10.14% |
| 2022-06-30 | $1.18B | $0.16B | 13.16% |
| 2022-03-31 | $1.14B | $0.21B | 18.21% |
| 2021-12-31 | $1.10B | $0.18B | 16.74% |
| 2021-09-30 | $1.04B | $0.14B | 13.21% |
| 2021-06-30 | $1.00B | $0.12B | 12.46% |
| 2021-03-31 | $0.96B | $0.12B | 12.42% |
| 2020-12-31 | $0.90B | $0.11B | 11.73% |
| 2020-09-30 | $0.87B | $0.12B | 13.26% |
| 2020-06-30 | $0.83B | $0.11B | 12.73% |
| 2020-03-31 | $0.78B | $0.08B | 10.57% |
| 2019-12-31 | $0.74B | $0.08B | 10.57% |
| 2019-09-30 | $0.69B | $0.07B | 10.37% |
| 2019-06-30 | $0.65B | $0.06B | 8.88% |
| 2019-03-31 | $0.60B | $0.05B | 8.67% |
| 2018-12-31 | $0.56B | $0.04B | 7.80% |
| 2018-09-30 | $0.53B | $0.03B | 4.91% |
| 2018-06-30 | $0.50B | $0.02B | 4.19% |
| 2018-03-31 | $0.49B | $0.01B | 2.67% |
| 2017-12-31 | $0.47B | $0.01B | 1.51% |
| 2017-09-30 | $0.44B | $0.00B | 0.68% |
| 2017-06-30 | $0.41B | $0.00B | 0.73% |
| 2017-03-31 | $0.39B | $0.01B | 1.29% |
| 2016-12-31 | $0.37B | $0.00B | 0.82% |
| 2016-09-30 | $0.35B | $0.00B | -1.15% |
| 2016-06-30 | $0.32B | $-0.02B | -6.50% |
| 2016-03-31 | $0.30B | $-0.03B | -11.11% |
| 2015-12-31 | $0.26B | $-0.03B | -12.50% |
| 2015-09-30 | $0.20B | $-0.02B | -10.77% |
| 2015-06-30 | $0.20B | $-0.01B | -5.03% |
| 2015-03-31 | $0.21B | $0.00B | -0.95% |
| 2014-12-31 | $0.23B | $0.00B | 1.30% |
| 2014-09-30 | $0.29B | $0.00B | 0.70% |
| 2014-06-30 | $0.27B | $-0.01B | -4.43% |
| 2014-03-31 | $0.26B | $-0.01B | -5.02% |
| 2013-12-31 | $0.25B | $-0.02B | -6.88% |
| 2013-09-30 | $0.24B | $-0.02B | -9.75% |
| 2013-06-30 | $0.23B | $-0.02B | -6.52% |
| 2013-03-31 | $0.22B | $-0.02B | -9.05% |
| 2012-12-31 | $0.21B | $-0.03B | -11.79% |
| 2012-09-30 | $0.20B | $-0.03B | -14.93% |
| 2012-06-30 | $0.19B | $-0.03B | -16.23% |
| 2012-03-31 | $0.17B | $-0.04B | -20.93% |
| 2011-12-31 | $0.15B | $-0.03B | -22.37% |
| 2011-09-30 | $0.13B | $-0.04B | -30.08% |
| 2011-06-30 | $0.11B | $-0.04B | -33.63% |
| 2011-03-31 | $0.10B | $-0.03B | -30.77% |
| 2010-12-31 | $0.10B | $-0.03B | -35.05% |
| 2010-09-30 | $0.09B | $-0.03B | -32.58% |
| 2010-06-30 | $0.08B | $-0.04B | -42.17% |
| 2010-03-31 | $0.08B | $-0.04B | -54.67% |
| 2009-12-31 | $0.07B | $-0.05B | -72.73% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $21.438B | $2.072B |
| Insulet Corporation is a leading developer, manufacturer and marketer of the Omnipod Insulin Management System. The system is equipped with a self-adhesive, small and lightweight disposable tubeless Omnipod device along with the wireless and handheld Personal Diabetes Manager (PDM). The Omnipod System is an innovative, discreet and easy-to-use continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System consists of Omnipod Insulin Management System ('Omnipod') and the Omnipod DASH Insulin Management System - Insulet's next generation digital mobile Omnipod platform. Insulet has tied up with pharmaceutical and biotechnological companies using customized form of the Omnipod System to deliver a drug at a certain administered volume and over a specified period of time. Insulet has partnered with pharmaceutical and biotechnology companies to tailor the Omnipod System technology platform for the delivery of subcutaneous drugs across other therapeutic areas. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $235.957B | 28.37 |
| Boston Scientific (BSX) | United States | $147.560B | 36.94 |
| Stryker (SYK) | United States | $144.011B | 30.11 |
| EssilorLuxottica (ESLOY) | France | $127.141B | 0.00 |
| Medtronic (MDT) | Ireland | $111.928B | 15.87 |
| Lonza Group Ag (LZAGY) | Switzerland | $50.371B | 0.00 |
| Haleon (HLN) | United Kingdom | $48.926B | 27.87 |
| ResMed (RMD) | United States | $36.560B | 27.46 |
| Agilent Technologies (A) | United States | $33.258B | 21.68 |
| GE HealthCare Technologies (GEHC) | United States | $33.082B | 15.71 |
| Terumo (TRUMY) | Japan | $26.680B | 34.65 |
| Koninklijke Philips (PHG) | Netherlands | $21.384B | 15.37 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.060B | 11.60 |
| Baxter (BAX) | United States | $15.713B | 11.73 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $12.872B | 0.00 |
| Demant (WILYY) | Denmark | $9.377B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $9.076B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.175B | 21.49 |
| Lantheus Holdings (LNTH) | United States | $5.385B | 13.58 |
| Prestige Consumer Healthcare (PBH) | United States | $4.149B | 18.54 |
| Perrigo (PRGO) | Ireland | $3.664B | 9.29 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Haemonetics (HAE) | United States | $3.367B | 15.34 |
| ICU Medical (ICUI) | United States | $3.250B | 23.96 |
| Envista Holdings (NVST) | United States | $3.127B | 25.99 |
| QuidelOrtho (QDEL) | United States | $1.954B | 13.44 |
| LeMaitre Vascular (LMAT) | United States | $1.833B | 40.97 |
| AtriCure (ATRC) | United States | $1.565B | 0.00 |
| Acuren (TIC) | United States | $1.357B | 0.00 |
| Neogen (NEOG) | United States | $1.200B | 15.36 |
| AdaptHealth (AHCO) | United States | $1.161B | 11.78 |
| Green Thumb Industries (GTBIF) | United States | $1.048B | 23.58 |
| BioLife Solutions (BLFS) | United States | $1.046B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.970B | 12.40 |
| Kestra Medical Technologies (KMTS) | United States | $0.904B | 0.00 |
| InMode (INMD) | Israel | $0.844B | 8.51 |
| Evolus (EOLS) | United States | $0.640B | 0.00 |
| CeriBell (CBLL) | United States | $0.624B | 0.00 |
| Owens & Minor (OMI) | United States | $0.602B | 4.99 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.542B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.538B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.524B | 0.00 |
| Valneva SE (VALN) | France | $0.510B | 0.00 |
| Surmodics (SRDX) | United States | $0.417B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.407B | 0.00 |
| SNDL (SNDL) | Canada | $0.339B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.337B | 12.41 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.329B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.329B | 58.50 |
| Canopy Growth (CGC) | Canada | $0.272B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.263B | 22.17 |
| Sanara MedTech (SMTI) | United States | $0.256B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.254B | 0.00 |
| ZimVie (ZIMV) | United States | $0.253B | 11.52 |
| Cerus (CERS) | United States | $0.252B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.245B | 0.00 |
| Quanterix (QTRX) | United States | $0.235B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.221B | 0.00 |
| Biote (BTMD) | United States | $0.207B | 5.82 |
| Brainsway (BWAY) | Israel | $0.206B | 54.50 |
| Omeros (OMER) | United States | $0.199B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.196B | 0.00 |
| Organigram Global (OGI) | Canada | $0.187B | 0.00 |
| High Tide (HITI) | Canada | $0.185B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.179B | 14.59 |
| Verano Holdings (VRNOF) | United States | $0.174B | 0.00 |
| Exagen (XGN) | United States | $0.152B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.140B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.131B | 16.18 |
| Jin Medical (ZJYL) | China | $0.107B | 0.00 |
| MacroGenics (MGNX) | United States | $0.096B | 0.00 |
| Fonar (FONR) | United States | $0.090B | 11.64 |
| Veru (VERU) | United States | $0.090B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.087B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.087B | 0.00 |
| Agape ATP (ATPC) | $0.084B | 0.00 | |
| TerrAscend (TSNDF) | Canada | $0.075B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.068B | 0.00 |
| InterCure (INCR) | Israel | $0.068B | 0.00 |
| Apyx Medical (APYX) | United States | $0.066B | 0.00 |
| Zynex (ZYXI) | United States | $0.064B | 0.00 |
| ImmuCell (ICCC) | United States | $0.059B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.054B | 0.00 |
| Modular Medical (MODD) | United States | $0.042B | 0.00 |
| Nephros (NEPH) | United States | $0.041B | 55.29 |
| United-Guardian (UG) | United States | $0.037B | 12.90 |
| Rockwell Medical (RMTI) | United States | $0.032B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.019B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.019B | 0.00 |
| Safety Shot (SHOT) | United States | $0.018B | 0.00 |
| Flora Growth (FLGC) | United States | $0.017B | 0.00 |
| INLIF (INLF) | $0.012B | 0.00 | |
| Trinity Biotech (TRIB) | Ireland | $0.011B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.011B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.008B | 0.00 |
| Senestech (SNES) | United States | $0.006B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.005B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |